Panel recommends Northwest Bio brain-cancer trial continue
(Reuters) - Northwest Biotherapeutics Inc on Friday said an independent monitoring board had recommended that a late-stage study of its experimental brain-cancer treatment be continued, based on an interim safety review.
The study involves more than 300 patients newly diagnosed with Glioblastoma multiforme, the most serious form of brain cancer. The main goal of the trial is to determine if the medicine, DCVax-L, can delay progression of the disease when taken on top of standard treatment.
Shares of Northwest Biotherapeutics rose 12 percent in premarket trading, from their closing price on Thursday of $5.96 on the Nasdaq.
It is a so-called immuno-oncology drug, meaning it spurs the body's own immune system to identify and kill cancer cells. Specifically, it harnesses dendritic cells, master cells of the immune system that give instructions to t-cells and b-cells, which make antibodies.
The drug consists of an individual patient's immature dendritic cells, which are drawn from the blood and exposed in a laboratory dish to antigens, or proteins, from brain tumor tissue of the patient obtained in surgery.
(Reporting by Ransdell Pierson; Editing by Steve Orlofsky)
- Israel rejects ceasefire plan, source says, as death toll nears 850 |
- Obama tells Central American leaders most children will go home
- First Ebola victim in Sierra Leone capital on the run
- Bad weather seen as probable cause of Air Algerie crash
- EU edges to economic sanctions on Russia but narrows scope |
Robert Blendon of the Harvard School of Public Health says the Affordable Care Act's unpopularity in 12 key states will keep it a central issue in the 2014 elections. Video